BIOMAT Database Logo BIOMAT Database Logo

[Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. 1992

M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
Department of Internal Medicine IV, Teikyo University School of Medicine, Kawasaki, Japan.

The anti-emetic effects, safety and usefulness of ondansetron, a 5-HT3 receptor antagonist, given orally once daily for 3-5 consecutive days, were investigated in patients receiving a high single dose (greater than or equal to 50 mg/m2 or 75 mg/body) or lower multiple doses (greater than or equal to 15-20 mg/m2/day for 3-5 consecutive days) of cisplatin. Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days. Efficacy rates in controlling nausea and emesis over the 3-5 days were 77.3% (17/22 cases) and 66.7% (6/9 cases) in patients receiving a high single dose and lower multiple doses of cisplatin, respectively. Side effects were observed in 2 cases (headache and elevation of blood pressure in one case and only headache in the other case.). Abnormality in clinical laboratory findings was observed in 1 case. From the above, ondansetron, showing high efficacy by oral administration 4 mg once daily for 3-5 consecutive days, without any problem in safety, was considered to be a useful anti-emetic agent.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
July 1992, Zhonghua zhong liu za zhi [Chinese journal of oncology],
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
June 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
December 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.
March 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy.
January 1998, The oncologist,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
Development and evaluation of buccal bioadhesive tablet of an anti-emetic agent ondansetron.
January 2009, AAPS PharmSciTech,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron.
April 1995, Anti-cancer drugs,
M Suminaga, and H Furue, and T Taguchi, and H Niitani, and K Ota, and S Tsukagoshi, and Y Ariyoshi, and M Ikeda, and Y Akasaka, and J Ohta
Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group.
March 1999, Clinical therapeutics,
Copied contents to your clipboard!